Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Inhaled Drug Delivery Conference: Industry Case Studies, Regulatory Updates, Latest Therapies and Technology Innovations - London, United Kingdom - November 6-7, 2019 - ResearchAndMarkets.com

October 14, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Oct 14, 2019--

The “Inhaled Drug Delivery” conference has been added to ResearchAndMarkets.com’s offering

This seminar includes presentations and knowledge-sharing from world-recognised experts from industry, academia and regulation in the area of respiratory medicines and is an essential event for all those new to or experienced in inhaler drug delivery.

Inhaled drug delivery is achieved using four principal technologies: dry powder inhalers, metered-dose inhalers, nebulisers and liquid inhalers. Although there are many differences between these technologies, there are a number of fundamental principles that are followed to achieve an effective delivered dose. This event will provide an excellent forum to share knowledge and explore the opportunities across the dose forms with key industry leaders.

The most recent and innovative developments in inhaled drug delivery will be addressed including the use of triple therapies in lung disease, the development of long-awaited generic inhalers, the use of quality by design (QbD) principles in continuous manufacture, innovation in nebuliser treatment, reviews of connected devices, and the use of human factors in the design process. Regulations are key to respiratory medicines and future European and UK regulatory processes following Brexit will be critical when developing product approval strategies. Regulatory issues on this and other important hot topics will be considered.

This programme will provide valuable insights into inhaled drug delivery from experts in the field and will give you:

Benefits of attending


Programme Day One


Chair’s welcome and introduction

Mike Holroyd

You can breathe easily now: modern respiratory medicines

Helen Muirhead

Innovation in nebulised therapy

Dr John Pritchard

New concepts for inhaled corticosteroid therapeutic equivalence

Peter Daly-Yates

INFORM 2020: new analytical insights into dry powder formulations for inhalation

Professor Darragh Murnane

Developing triple combination inhalers

Enrico Zambelli

Bringing better inhaled drugs faster to market through functional respiratory imaging (FRI) and artificial intelligence (AI)

- Facilitate the development of novel treatments in COPD

- Assist in tackling environmental challenges such as wildfire exposure

Jan de Backer

Digitally enabled inhalers - a clinician’s perspective

Richard Costello

Technology transfer (TT) for inhaled drugs

Bruce Davis

Discussion session

Programme Day two

Review of day one

Helen Muirhead

Review of new inhalation technologies

Mike Holroyd

How to navigate a smooth regulatory pathway for inhaled products

Ian Ashurst

Regulatory alignment between the UK and Europe post Brexit

Dr David Jefferys

Human factors (HF) studies - a hype or a must-do?

Richard Featherstone

Handling fourses for the different use of inhaler devices

Dr Herbert Wachtel

Inhaler devices and the environment

Chris Baron

Could smart inhalers dramatically change the way that asthma and COPD patients are treated?

Alison Moore

Chair’s closing remarks

For more information about this conference visit https://www.researchandmarkets.com/r/ren1a

View source version on businesswire.com:https://www.businesswire.com/news/home/20191014005260/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 10/14/2019 05:36 AM/DISC: 10/14/2019 05:36 AM